Biotronik today announced positive results from a clinical trial for its Neuro Prospera spinal cord stimulation (SCS) system. The BENEFIT-02 trial evaluates the Resonance multiphase stimulating paradigm used in the Neuro Prospera system. It looked at the safety and effectiveness of the stimulator in treating patients with chronic pain. Contrary to other currently available SCS […]
Neuromodulation/Neurostimulation
How Onward uses spinal cord stimulation — and perhaps BCI — to restore movement
The brain-computer interface space has taken medtech by storm. This novel approach from Onward has the potential to bring it to another level. Several companies are developing brain-computer interfaces (BCIs), many of which offer people with paralysis a chance to control external devices with their mind. Onward, a Dutch medtech company, develops technology that could […]
Medtronic has a new president of its Neuromodulation business
Medtronic announced today that it appointed Paolo Di Vincenzo as the president of its Neuromodulation business. Di Vincenzo’s appointment at Medtronic goes into effect on Oct. 30. In his new role, he holds responsibilities for the overall strategic direction of the company’s neuromodulation business and day-to-day operations. Nnamdi Njoku, Medtronic’s previous Neuromodulation business president, left […]
Onward announces first-in-human implant of stimulator with BCI
Onward Medical announced today that it completed the first-in-human implant of its ARC-IM stimulator for restoring upper extremity function. Eindhoven, The Netherlands-based Onward designed the stimulator to restore function after spinal cord injury (SCI). The patient also received a wireless brain-computer interface (BCI) for initiating thought-driven movement when paired with ARC-IM. Onward’s ARC-IM delivers targeted, […]
Relievant Medsystems unveils Intracept simulation training program
Relievant Medsystems announced today that it released its Intracept simulator system, a training platform for the Intracept procedure. Further progress for Relievant and Intracept follows Tuesday’s major news of an agreement for Boston Scientific to acquire the company. Boston Scientific officials went into further detail on their expectations for the Relievant deal at the company’s […]
Tivic Health regains Nasdaq compliance
Tivic Health (Nasdaq:TIVC) announced today that it regained compliance with the minimum bid price requirement on the Nasdaq market. Earlier this year, San Francisco-based Tivic filed an SEC Form 8-K pertaining to a notice of delisting from the Nasdaq market. The company received notice in January that its closing price fell below $1 for 30 […]
Boston Scientific targets M&A, AI to reach ‘next level’
Mike Mahoney uses fantasy football to describe Boston Scientific : He says that, if creating a medtech team, “it would be the draft you want.” Speaking at the company’s 2023 Investor Day event, the CEO set the theme as “next level.” He explained his aim to make Boston Scientific a “compelling” and “fantastic place to […]
Neuralink opens recruitment for first-in-human BCI trial
Neuralink, the Elon Musk-backed brain-computer interface (BCI) maker, today announced that it opened recruitment for a clinical trial. The first-in-human trial — the PRIME study — evaluates the company’s fully implantable, wireless BCI and delivering surgical robot. It assesses the initial functionality of the BCI for enabling people with paralysis to control external devices with […]
InBrain Neuroelectronics wins FDA breakthrough nod for intelligent network modulation system
InBrain Neuroelectronics announced today that it received FDA breakthrough device designation for its intelligent network modulation system. The breakthrough nod covers the graphene-neural platform as an adjunctive therapy for treating Parkinson’s disease. InBrain’s system harnesses the power of graphene, a two-dimensional material made of a lattice of carbon atoms. The thin material — stronger than […]
FDA grants IDE to Orchestra BioMed for cardiac neuromod trial in pacemaker patients
Orchestra BioMed (Nasdaq:OBIO) announced today that the FDA granted investigational device exemption (IDE) for its BACKBEAT trial. BACKBEAT (bradycardia pacemaker with atrioventricular interval modulation for blood pressure treatment) evaluates the safety and efficacy of atrioventricular interval modulation (AVIM) therapy. Also known as BackBeat CNT, it treats hypertensive patients indicated for a dual-chamber cardiac pacemaker. New […]
Boston Scientific to acquire nerve ablation tech developer Relievant Medsystems for $850M
Boston Scientific announced today that it entered into a definitive agreement to acquire Relievant Medsystems. The transaction includes an upfront cash payment of $850 million. Additional payments are contingent on sales performance over the next three years. Minneapolis-based Relievant developed and commercialized the Intracept intraosseous nerve ablation system for chronic pain. The minimally invasive, FDA-cleared, […]